For the 10,000+ people
who have been treated with SPINRAZA worldwide,*
victories are personal.

*Based on commercial patients, early access patients, and clinical trial participants through December 2019.

Discover SPINRAZA: the first FDA-
approved treatment for SMA

6+ years

Safety and efficacy
in the longest
clinical trial in
SMA to date


SPINRAZA is delivered directly to

the central nervous system (CNS)
motor neuron loss begins.
initial loading doses,
given 3 times a year.

From 3 days to 80 years old‡§

There’s someone from almost every age group who has been treated with SPINRAZA.

Includes clinical trial patients.

Clinical studies of SPINRAZA did not include sufficient numbers of subjects aged 65 and older to determine
whether they respond differently from younger patients.

§Based on commercial patients in the US (including Puerto
Rico) through December 2019.

Demonstrated efficacy in people with early and later-onset SMA

Safety & side effects

The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA.

How SPINRAZA works

SPINRAZA targets an underlying cause of muscle weakness in SMA.